Nature of Quiet Sun Oscillations Using Data from the Hinode, TRACE, and SOHO Spacecraft

We study the nature of quiet-Sun oscillations using multi-wavelength observations from TRACE, Hinode, and SOHO. The aim is to investigate the existence of propagating waves in the solar chromosphere and the transition region by analyzing the statistical distribution of power in different locations, e.g. in bright magnetic (network), bright non-magnetic and dark non-magnetic (inter-network) regions, separately. We use Fourier power and phase-difference techniques combined with a wavelet analysis. Two-dimensional Fourier power maps were constructed in the period bands 2 -aEuro parts per thousand 4 minutes, 4 -aEuro parts per thousand 6 minutes, 6 -aEuro parts per thousand 15 minutes, and beyond 15 minutes. We detect the presence of long-period oscillations with periods between 15 and 30 minutes in bright magnetic regions. These oscillations were detected from the chromosphere to the transition region. The Fourier power maps show that short-period powers are mainly concentrated in dark regions whereas long-period powers are concentrated in bright magnetic regions. This is the first report of long-period waves in quiet-Sun network regions. We suggest that the observed propagating oscillations are due to magnetoacoustic waves, which can be important for the heating of the solar atmosphere.

Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and In vivo activity

The natural product fumagillin exhibits potent antiproliferative and antiangiogenic properties. The semisynthetic analog PPI-2458, (3R,4S,5S,6R)-5-methoxy-4-(2R,3R)-2-methyl-3-(3-methylbut-2-enyl) oxiran-2-yl]-1-oxaspiro2.5]octan-6-yl] N-(2R)-1-amino-3-methyl-1-oxobutan-2-yl]carbamate, demonstrates rapid inactivation of its molecular target, methionine aminopeptidase-2 (MetAP2), and good efficacy in several rodent models of cancer and inflammation with oral dosing despite low apparent oral bioavailability. To probe the basis of its in vivo efficacy, the metabolism of PPI-2458 was studied in detail. Reaction phenotyping identified CYP3A4/5 as the major source of metabolism in humans. Six metabolites were isolated from liver microsomes and characterized by mass spectrometry and nuclear resonance spectroscopy, and their structures were confirmed by chemical synthesis. The synthetic metabolites showed correlated inhibition of MetAP2 enzymatic activity and vascular endothelial cell growth. In an ex vivo experiment, MetAP2 inhibition in white blood cells, thymus, and lymph nodes in rats after single dosing with PPI-2458 and the isolated metabolites was found to correlate with the in vitro activity of the individual species. In a phase 1 clinical study, PPI-2458 was administered to patients with non-Hodgkin lymphoma. At 15 mg administered orally every other day, MetAP2 in whole blood was 80% inactivated for up to 48 hours, although the exposure of the parent compound was only similar to 10% that of the summed cytochrome P450 metabolites. Taken together, the data confirm the participation of active metabolites in the in vivo efficacy of PPI-2458. The structures define a metabolic pathway for PPI-2458 that is distinct from that of TNP-470 ((3R, 4S, 5S, 6R)-5-methoxy-4-(2R, 3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro2.5]octan-6 -yl] N-(2-chloroacetyl)carbamate). The high level of MetAP2 inhibition achieved in vivo supports the value of fumagillin-derived therapeutics for angiogenic diseases.